title: [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer].
abstract: We performed a pilot study of combination chemotherapy with TS-1 and cisplatin for highly advanced gastric cancer. From June 2002, 12 patients with multiple liver metastases, carcinomatous lymphangitis or peritoneal dissemination, were enrolled in the study. TS-1 was administered at a daily dose on day 1-21 and an intermediate-dose of cisplatin (60 mg/m2) was administered on day 8. The combination was repeated in a 5-week cycle. The median administered cycles were three (one to eight). An objective response was obtained in 9 cases (75.0%) of primary sites and 6 cases of metastatic sites. No severe hematological toxicity occurred, and grade 3 stomatitis (in one case) and vomiting (in two cases) occurred as non-hematological toxicities. The improvement of clinical symptoms such as appetite loss and abdominal discomfort was obtained in 9 of 10 cases. The median survival time is 244 days. The TS-1/CDDP regimen had almost no survival benefits, but may induce relief of symptoms due to cancer and better quality of life.
authors.affiliation: Division of Gasttroenterlogy. Chiba University.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Sakai
authors.forename: Takashi
authors.initials: T
authors.lastname: Saotome
authors.forename: Mototsugu
authors.initials: M
authors.lastname: Fujimori
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shimizu
authors.forename: Takashi
authors.initials: T
authors.lastname: Inkyo
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Yugeta
authors.forename: Masamichi
authors.initials: M
authors.lastname: Ohbu
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Koma
authors.forename: Tsunenobu
authors.initials: T
authors.lastname: Sato
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Nagashima
authors.forename: Akira
authors.initials: A
authors.lastname: Hayasaka
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Fukuyama
authors.forename: Shin
authors.initials: S
authors.lastname: Tsuchiya
authors.forename: Toshio
authors.initials: T
authors.lastname: Tsuyuguchi
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Saisho
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D010865:Pilot Projects; D011725:Pyridines / Q000008:administration & dosage; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel; D002945:Cisplatin